Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA9 | Q16790 | 6/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802193 | 0.89 | PTGES (0.83) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL976823 | 0.88 | PTGES (1.00) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL2801478 | 0.86 | PTGES (0.78) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL2804978 | 0.85 | PTGES (0.68) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL2805760 | 0.82 | PTGES (0.79) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL2801489 | 0.82 | PTGES (0.83) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL2806370 | 0.82 | PTGES (0.83) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL979176 | 0.80 | PTGES (0.78) | PTGESCA12CA2CA9 | |
| SCHEMBL2803372 | 0.79 | PTGES (0.69) | PTGESCA12CA2CA9CA1 | |
| SCHEMBL981396 | 0.79 | PTGES (0.77) | PTGESCA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | claimed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PTGES 9/4885CA12 4708/4885CA2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.